Mortality Rates in Trials of Subjects With Type 2 Diabetes

被引:71
作者
Barkoudah, Ebrahim [1 ,2 ]
Skali, Hicham [1 ]
Uno, Hajime [3 ]
Solomon, Scott D. [1 ]
Pfeffer, Marc A. [1 ]
机构
[1] Brigham & Womens Hosp, Cardiovasc Div, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Div Gen Med, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
来源
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2012年 / 1卷 / 01期
关键词
type; 2; diabetes; chronic kidney disease; mortality; controlled clinical trials; randomized; CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR-DISEASE; PRIMARY PREVENTION; DARBEPOETIN-ALPHA; CLINICAL-TRIALS; GLUCOSE CONTROL; MELLITUS; OUTCOMES; EVENTS; RISK;
D O I
10.1161/JAHA.111.000059
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-In randomized controlled trials (RCTs) of subjects with type 2 diabetes mellitus, mortality rates vary substantially. We sought to examine the inclusion and exclusion criteria of these RCTs to explore relationships with mortality. Methods and Results-MEDLINE database was searched from August 1980 through March 2011. Selection criterion included published RCTs of adults with type 2 diabetes mellitus of at least 1000 patients, reporting all-cause mortality and having follow-up duration of at least 1 year. Twenty-two trials were eligible. Annualized mortality rates were derived. Inclusion and exclusion criteria were tabulated for each trial. Trials were categorized in 4 groups according to annual mortality rates: <1, >= 1 to <2, >= 2 to <4, and >= 4 per 100 patient-years. The analysis cohort included 91842 patients and 6837 deaths. Mortality rates ranged from 0.28 to 8.24 per 100 patient-years. Patients enrolled in the highest mortality category were more likely to be older and had longer diabetes duration and higher blood pressure. The selection for hypertension was common in the low-as well as high-mortality trials. Although the mortality rates were higher in RCTs with prior cardiovascular morbidity, the selection for chronic kidney disease-defined by either higher serum creatinine or lower estimated glomerular filtration rate and/or the presence of proteinuria-was associated with the highest mortality rates. Conclusions-In this analysis of RCTs of type 2 diabetes mellitus, a 29-fold difference in annualized mortality was observed. In these RCTs, selection for renal disease, defined by either decline in renal function or presence of proteinuria, portends important mortality risk.
引用
收藏
页码:8 / 15
页数:8
相关论文
共 43 条
  • [1] Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)
    Adler, AI
    Stevens, RJ
    Manley, SE
    Bilous, RW
    Cull, CA
    Holman, RR
    [J]. KIDNEY INTERNATIONAL, 2003, 63 (01) : 225 - 232
  • [2] A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
    Frye R.L.
    August P.
    Brooks M.M.
    Hardison R.M.
    Kelsey S.F.
    MacGregor J.M.
    Orchard T.J.
    Chaitman B.R.
    Genuth S.M.
    Goldberg S.H.
    Hlatky M.A.
    Jones T.L.Z.
    Molitch M.E.
    Nesto R.W.
    Sako E.Y.
    Sobel B.E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (24) : 2503 - 2515
  • [3] Bland JM, 1998, BRIT MED J, V316, P129
  • [4] Does Diabetes Always Confer Coronary Heart Disease Risk Equivalent to a Prior Myocardial Infarction? Implications for prevention
    Boyko, Edward J.
    Meigs, James B.
    [J]. DIABETES CARE, 2011, 34 (03) : 782 - 784
  • [5] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    Brenner, BM
    Cooper, ME
    de Zeeuw, D
    Keane, WF
    Mitch, WE
    Parving, HH
    Remuzzi, G
    Snapinn, SM
    Zhang, ZX
    Shahinfar, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 861 - 869
  • [6] Primary prevention of cardiovascular diseases in people with diabetes mellitus - A scientific statement from the American Heart Association and the American Diabetes Association
    Buse, John B.
    Ginsberg, Henry N.
    Bakris, George L.
    Clark, Nathaniel G.
    Costa, Fernando
    Eckel, Robert
    Fonseca, Vivian
    Gerstein, Hertzel C.
    Grundy, Scott
    Nesto, Richard W.
    Pignone, Michael P.
    Plutzky, Jorge
    Porte, Daniel
    Redberg, Rita
    Stitzel, Kimberly F.
    Stone, Neil J.
    [J]. CIRCULATION, 2007, 115 (01) : 114 - 126
  • [7] Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
    Colhoun, HM
    Betteridge, DJ
    Durrington, PN
    Hitman, GA
    Neil, HAW
    Livingstone, SJ
    Thomason, MJ
    Mackness, MI
    Charlton-Menys, V
    Fuller, JH
    [J]. LANCET, 2004, 364 (9435) : 685 - 696
  • [8] Comparative outcomes study of metformin intervention versus conventional approach - The COSMIC approach study
    Cryer, DR
    Nicholas, SP
    Henry, DH
    Mills, DJ
    Stadel, BV
    [J]. DIABETES CARE, 2005, 28 (03) : 539 - 543
  • [9] Association Between Cardiac Biomarkers and the Development of ESRD in Patients With Type 2 Diabetes Mellitus, Anemia, and CKD
    Desai, Akshay S.
    Toto, Robert
    Jarolim, Petr
    Uno, Hajime
    Eckardt, Kai-Uwe
    Kewalramani, Reshma
    Levey, Andrew S.
    Lewis, Eldrin F.
    McMurray, John J. V.
    Parving, Hans-Henrik
    Solomon, Scott D.
    Pfeffer, Marc A.
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2011, 58 (05) : 717 - 728
  • [10] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
    Dormandy, JA
    Charbonnel, B
    Eckland, DJA
    Erdmann, E
    Massi-Benedetti, M
    Kmoules, IK
    Skene, AM
    Tan, MH
    Lefébvre, PJ
    Murray, GD
    Standl, E
    Wilcox, RG
    Wlhelmsen, L
    Betteridge, J
    Birkeland, K
    Golay, A
    Heine, RJ
    Korányi, L
    Laakso, M
    Mokán, M
    Norkus, A
    Pirags, V
    Podar, T
    Scheen, A
    Scherbaum, W
    Schernthaner, G
    Schmitz, O
    Skrha, J
    Smith, U
    Taton, J
    [J]. LANCET, 2005, 366 (9493) : 1279 - 1289